ADAP

Enable Biosciences Publishes Study Revealing ADAP Technology's Improved Accuracy in T1D Risk Prediction

Retrieved on: 
Tuesday, February 13, 2024

Detailed findings are presented in the article "Advances in risk predictive performance of pre-symptomatic type 1 diabetes via the multiplex Antibody-Detection-by-Agglutination-PCR (ADAP) assay," published in Frontiers of Endocrinology.

Key Points: 
  • Detailed findings are presented in the article "Advances in risk predictive performance of pre-symptomatic type 1 diabetes via the multiplex Antibody-Detection-by-Agglutination-PCR (ADAP) assay," published in Frontiers of Endocrinology.
  • This pivotal study underscores the ADAP assay's ability to detect islet autoantibodies, which are indicative of a high risk of progression to clinical T1D.
  • Dr. Jason Tsai, PhD, CTO of Enable Biosciences, elaborates on the significance of the findings: "These study results reinforce the strength of our ADAP technology in early T1D detection.
  • For more insights into Enable Biosciences and the impact of their ADAP technology, please visit www.enablebiosciences.com .

Enable Biosciences Inc. Reveals Key Findings on COVID-19 Transmission from Mothers to Newborns

Retrieved on: 
Wednesday, January 3, 2024

This research is crucial in understanding how maternal antibodies against SARS-CoV-2 are transferred to and persist in newborns.

Key Points: 
  • This research is crucial in understanding how maternal antibodies against SARS-CoV-2 are transferred to and persist in newborns.
  • The study involved analyzing dried blood spots from newborns for the presence of these antibodies.
  • With 15.7% of newborns testing positive, the study provides new insights into the prevalence and longevity of maternal antibodies, highlighting a significant maternal transmission rate.
  • Dr. Jason Tsai, CTO of Enable Biosciences, commented, "This study is a landmark in neonatal research, offering unprecedented insights into maternal-to-neonatal antibody transfer.

Appen Teams Up with AWS to Drive AI Innovation

Retrieved on: 
Tuesday, November 21, 2023

With this expanded relationship, Appen is integrating cutting-edge services from AWS to strengthen its AI data platform, which serves as the interface between humans and AI.

Key Points: 
  • With this expanded relationship, Appen is integrating cutting-edge services from AWS to strengthen its AI data platform, which serves as the interface between humans and AI.
  • Appen is now working with the AWS Generative AI Innovation Center to develop a new Appen solution, Assessment AI, to address the challenge of qualifying domain experts at scale.
  • “This new effort with the AWS Generative AI Innovation Center is a game-changer for enterprises building safe and trusted AI applications.
  • “We are delighted to work closely with Appen, as they advance their generative AI capabilities with Assessment AI,” said Sri Elaprolu, global head of the AWS Generative AI Innovation Center, which pairs customers with AWS AI/ML science and strategy experts.

Enable Biosciences Receives $3M Phase IIB SBIR Award from NIDDK for Advanced T1D Testing Technology

Retrieved on: 
Tuesday, December 19, 2023

A key objective of this funding is to pursue FDA clearance for the T1D test, a critical step towards commercialization.

Key Points: 
  • A key objective of this funding is to pursue FDA clearance for the T1D test, a critical step towards commercialization.
  • Dr. Jason Tsai, PhD, Chief Technical Officer at Enable Biosciences, shared his enthusiasm: "This Phase IIB SBIR award from NIDDK is a testament to our dedication to transforming T1D testing.
  • The NIDDK's support is pivotal for Enable Biosciences in its pursuit of FDA clearance for its innovative T1D test.
  • For more information about Enable Biosciences and their cutting-edge approach to T1D testing, visit www.enablebiosciences.com or contact their media team for further details and inquiries.

AHF Rebukes Gilead Sciences As Prime Lawbreaking Drug Profiteer

Retrieved on: 
Wednesday, May 3, 2023

AIDS Healthcare Foundation ( AHF ), the world’s largest HIV and AIDS healthcare provider, continued to expose Gilead Sciences’ despicable greed, as the company – maker of key HIV, hepatitis C, and COVID-19 drugs – hosted its virtual Annual General Meeting (AGM) Wednesday morning.

Key Points: 
  • AIDS Healthcare Foundation ( AHF ), the world’s largest HIV and AIDS healthcare provider, continued to expose Gilead Sciences’ despicable greed, as the company – maker of key HIV, hepatitis C, and COVID-19 drugs – hosted its virtual Annual General Meeting (AGM) Wednesday morning.
  • Gilead keeps racking up exorbitant profits while restricting access to lifesaving medications.
  • Restoration of the Advancing Access Medication Assistance Program terms that were in effect prior to January 1, 2022.
  • Restoration of the sub-ceiling pricing for Descovy that was available to all covered entities prior to January 1, 2022.”
    To date, AHF has received no reply from Gilead or Mr. O’Day.

TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR

Retrieved on: 
Wednesday, April 26, 2023

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TCR² Therapeutics Inc. (NasdaqGS: TCRR) to Adaptimmune Therapeutics plc (NasdaqGS: ADAP).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TCR² Therapeutics Inc. (NasdaqGS: TCRR) to Adaptimmune Therapeutics plc (NasdaqGS: ADAP).
  • Under the terms of the proposed transaction, shareholders of TCR² will receive 1.5117 ADS of Adaptimmune for each share of TCR² that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

ALERT: The M&A Class Action Firm Continues Investigating the Merger – CNXC, INDT, HSKA, ADAP

Retrieved on: 
Wednesday, April 12, 2023

Under the terms of the agreement, CNXC shareholders are expected to own approximately 78% of the combined company.

Key Points: 
  • Under the terms of the agreement, CNXC shareholders are expected to own approximately 78% of the combined company.
  • INDUS Realty Trust, Inc. (NASDAQ: INDT ), relating to its proposed sale to affiliates of Centerbridge Partners, L.P. and GIC Real Estate, Inc..
  • Adaptimmune Therapeutics plc (NASDAQ: ADAP ), relating to its proposed merger with TCR² Therapeutics Inc.
  • Under the terms of the agreement, ADAP shareholders are expected to own approximately 75% of the combined company.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – MLVF, SAL, ADAP, BRBW

Retrieved on: 
Wednesday, April 5, 2023

Under the terms of the agreement, MLVF shareholders will receive 0.7733 shares of First Bank and $7.80 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, MLVF shareholders will receive 0.7733 shares of First Bank and $7.80 in cash per share they own.
  • It is free and there is no cost or obligation to you.
  • Salisbury Bancorp, Inc. (NASDAQ: SAL ), relating to its proposed merger NBT Bancorp, Inc.
  • Under the terms of the merger, SAL shareholders will receive 0.745 shares of NBT per share they own.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – ADAP, SAL, BRBW, MLVF

Retrieved on: 
Wednesday, March 29, 2023

Under the terms of the agreement, ADAP shareholders are expected to own approximately 75% of the combined company.

Key Points: 
  • Under the terms of the agreement, ADAP shareholders are expected to own approximately 75% of the combined company.
  • Salisbury Bancorp, Inc. (NASDAQ: SAL ), relating to its proposed merger NBT Bancorp, Inc.
  • Under the terms of the merger, SAL shareholders will receive 0.745 shares of NBT per share they own.
  • Under the terms of the agreement, MLVF shareholders will receive 0.7733 shares of First Bank and $7.80 in cash per share they own.

ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – MLVF, ADAP, BRBW, SAL

Retrieved on: 
Wednesday, March 22, 2023

Under the terms of the agreement, MLVF shareholders will receive 0.7733 shares of First Bank and $7.80 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, MLVF shareholders will receive 0.7733 shares of First Bank and $7.80 in cash per share they own.
  • Adaptimmune Therapeutics plc (NASDAQ: ADAP ), relating to its proposed merger with TCR² Therapeutics Inc.
  • Salisbury Bancorp, Inc. (NASDAQ: SAL ), relating to its proposed merger NBT Bancorp, Inc.
  • Under the terms of the merger, SAL shareholders will receive 0.745 shares of NBT per share they own.